@article{JTD16252,
author = {Shinkyo Yoon and Dae Ho Lee and Sang-We Kim},
title = {Comments on the trial of cisplatin and etoposide plus thoracic radiotherapy followed by nivolumab or placebo for locally advanced non-small cell lung cancer (RTOG 3505)},
journal = {Journal of Thoracic Disease},
volume = {9},
number = {10},
year = {2017},
keywords = {},
abstract = {Radiotherapy (RT) induce lethal DNA damage to tumor cells and the concurrent chemoradiation (CCRT) is the standard treatment option for inoperable stage III non-small cell lung cancer (NSCLC) until now (1). The expectancy of 5-year survival, however, is less than 20–25%. Thus, some modification or addition of new treatment modality would be a reasonable approach to improve its cure rate.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/16252}
}